Changes in the Immune Phenotype and Gene Expression Profile Driven by a Novel Tuberculosis Nanovaccine: Short and Long-Term Post-immunization

Amparo Martínez-Pérez1,2, Ana Igea1,2, Olivia Estévez1,2, Catarina M. Ferreira3,4, Egídio Torrado3,4, António Gil Castro3,4, Carmen Fernández5, Anna-Lena Spetz5, Lucille Adam5, Moisés López González5, Mahavir Singh6, Rajko Reljic7 and África González-Fernández1,2*

1 Immunology Group, CINBIO, Universidade de Vigo, Vigo, Spain, 2 Galicia Sur Health Research Institute (IIS-GS), Hospital Alvaro Cunqueiro, Vigo, Spain, 3 Life and Health Sciences Research Institute, University of Minho, Braga, Portugal, 4 ICVS/38’s-PT Government Associate Laboratory, Braga/Guimarães, Portugal, 5 Department of Molecular Biosciences, The Wenner-Gren Institute (MBW) Stockholm University, Stockholm, Sweden, 6 Lionex GmbH, Braunschweig, Germany, 7 Infection and Immunity Research Institute, St George's, University of London, London, United Kingdom

Deciphering protection mechanisms against Mycobacterium tuberculosis (Mtbb) remains a critical challenge for the development of new vaccines and therapies. We analyze the phenotypic and transcriptomic profile in lung of a novel tuberculosis (TB) nanoparticle-based boosting mucosal vaccine Nano-FP1, which combined to BCG priming conferred enhanced protection in mice challenged with low-dose Mtbb. We analyzed the vaccine profile and efficacy at short (2 weeks), medium (7 weeks) and long term (11 weeks) post-vaccination, and compared it to ineffective Nano-FP2 vaccine. We observed several changes in the mouse lung environment by both nanovaccines, which are lost shortly after boosting. Additional boosting at long-term (14 weeks) recovered partially cell populations and transcriptomic profile, but not enough to enhance protection to infection. An increase in both total and resident memory CD4 and CD8 T cells, but no pro-inflammatory cytokine levels, were correlated with better protection. A unique gene expression pattern with differentially expressed genes revealed potential pathways associated to the immune defense against Mtbb. Our findings provide an insight into the critical immune responses that need to be considered when assessing the effectiveness of a novel TB vaccine.

Keywords: Mycobacterium tuberculosis, nanovaccines, immune protection, lung infection, transcriptomic analysis

INTRODUCTION

Despite being well-known and treated for years, tuberculosis (TB) is the leading cause of death from a single infectious pathogen worldwide. The World Health Organization estimates that one third of the world’s population carries the bacillus in a latent form, with a 10% probability of those infected to develop TB during their lifetime, and that contributes to 10 million new cases of TB occur yearly (1).
Control of the global TB epidemic has been challenged by the lack of an effective vaccine. Bacille Calmette–Guérin (BCG) remains the only licensed TB vaccine, although its efficacy against the pulmonary form of TB in adulthood is highly variable (2, 3). Unfortunately, the development of novel effective vaccines is hampered by the limited knowledge we have of the mechanisms that provide protection against Mycobacterium tuberculosis (Mtb).

The immune response against Mtb is complex and incompletely characterized. Although evidence supports the fundamental role of CD4+ T cells and cytokines (such as interferon gamma (IFNγ)) (4, 5), tumor necrosis factor alpha (TNFα), interleukins 2 (IL-2) (6–9), and 12 (IL-12) (10, 11)) in TB, there are still no reliable correlates of protection. In this scenario, it becomes difficult to predict the outcome of the disease or to monitor the efficacy of novel vaccines.

Mucosal vaccination (12–18) and mucosal boosting of BCG, combining the overall protection conferred by BCG with the reinforcement of the mucosal immunity in the lungs (19–25), have been considered attractive strategies against pulmonary TB. Hart et al. (26) demonstrated that the combination of subcutaneous BCG plus two intranasal boosts of a novel nanovaccine, Nano-FP1, significantly reduced the bacterial burden in mouse lungs after TB infection. Nano-FP1 is based on nanoparticles produced by the emulsification of yellow carnauba (YC) palm wax with sodium myristate (NaMA), coated with a fusion protein made of three different antigens of Mtb: the secreted protein Ag85B, the 16-kDa latency induced protein alpha crystalline (Acr) and the heparin-binding hemagglutinin (HBHA). Similar boosting nanovaccines based on other antigen combinations were also tested, but they did not show improved efficacy against Mtb (R. Reljic, unpublished). Among them is the Nano-FP2 vaccine, which displayed one single antigen replacement in its fusion protein compared to Nano-FP1, with antigen Ag85b replaced by the Mannose Binding Protein 64 (MPT64).

We intend to identify a phenotypic and/or transcriptomic profile of the efficacy of the Nano-FP1 TB vaccine in mice. Herein, we performed a systematic analysis of the novel Nano-FP1 prototype, analyzing the cellular signature and gene expression profile triggered in the pulmonary environment. Nano-FP2 was also tested as an example on a non-protective vaccine candidate. The effect produced by the intranasal boost with Nano-FP1 on previously BCG-immunized mice was evaluated at short-term (2 weeks), medium-term (7 weeks), and long-term (11 weeks) intervals. We found a unique cellular and transcriptional profile at short-term, characterized by alterations in CD4+ T cell populations and marked changes in gene expression. Nonetheless, we observed that the boosting effect was transient and it did not trigger an effective immunological memory against TB long term. Our findings suggest a critical role for the long-lived CD4+ T cell immunity that should be mandatory when assessing the effectiveness of a novel TB vaccine.

MATERIALS AND METHODS

Mice

Six-week-old female specific pathogen-free C57BL/6 mice were purchased from Envigo (Spain). The mice were maintained under barrier conditions in a BL-3 biohazard animal facility at the University of Minho, Braga, Portugal, with constant temperature (24 ± 1°C) and humidity (50 ± 5%). The animals were fed a sterile commercial mouse diet and provided with water ad libitum under standardized light-controlled conditions (12 h light and dark periods). The mice were monitored daily, and none of the mice exhibited any clinical symptoms or illness during this experiment.

For the early response experiment, 6-week-old female specific pathogen-free C57BL/6 mice were purchased from Scanbur (Denmark), and housed in pathogen-free conditions at the Animal Department of MBW, Stockholm University, Sweden. Mice were acclimatized for at least 1 week before use and supervised daily. The specified pathogen-free condition of the facility was confirmed by continuous use of sentinel mice.

All animal experiments were performed with ethical approval from the hosting institutions and according to the national regulations and legislation of that country.

The study was approved by and performed in accordance with guidelines of the CEEA Xunta de Galicia, code ES360570215601/17/INV. MED.02.OUTROS04/AGF/02. Early response experiments were approved by and performed in accordance with guidelines of the Stockholm North Ethical Committee on Animal Experiments, permit number N170/15.

Novovaccines Formulation

Two different vaccine candidates were used as intranasal (in) boost to BCG, hereafter referred to as Nano-FP1 and Nano-FP2. Both candidates consist of a combination of yellow carnauba palm wax with sodium myristate (YC-NaMA) nanoparticles (NPs) (Bethlehem, PA, USA) and a fusion protein (FP) composed of an N-terminal histidine tag and the Mtb antigens Acr (Rv2031c), Ag85B (Rv1886c), and the heparin-binding domain of HBHA (Rv0475) (FP1) or MPT64 (Rv1980c), Acr and HBHA (FP2). The vaccine formulation included 0.1% Yc-NaMA NPs, 200 µg/ml of the corresponding FP and 400 µg/ml PolyI:C (Sigma Aldrich) in saline solution, with 50 µl delivered to the each mouse. Nano-FP1 was used as the prototype of interest, taking into account previous studies reporting its protective effect (26) and Nano-FP2 was used as a representative of a nonprotective vaccine candidate (data not shown).

Study Groups and Immunization Protocol

The vaccination groups and schedules are shown in Figures 1A and 2A. For subcutaneous (s.c.) priming vaccination, mice received 0.5 million CFUs of BCG strain Pasteur. Twelve and 14 weeks later, mice from the Nano-FP1 and Nano-FP2 groups were anesthetized with 100 µl of ketamine–xylazine and 50 µl of the corresponding nanovaccine was intranasally administered. A group of mice were also administered a 3rd boost of the corresponding nanovaccine 25 weeks after sc. BCG. Animals were divided in four experimental groups: Unvaccinated mice (henceforth referred to as Naïve group); mice vaccinated with subcutaneous (s.c.) BCG alone (BCG group); mice vaccinated with BCG s.c. and 12 weeks later an intranasal boost with Nano-FP1 (BCG/Nano-FP1 group) or Nano-FP2 (BCG/Nano-FP2 group). Animals were studied at different time points (2, 7,
and 11 weeks (after two intranasal challenges), and 14 weeks (after an additional third intranasal challenge).

For the early immune experiment (24 h), mice were subcutaneously vaccinated with either 0.5 million CFUs of BCG or PBS. Twelve weeks later, they were administered intranasally one dose of either Nano-FP1 or PBS. 24 h later, mice were sacrificed. Animals were divided in four experimental groups (1): mice receiving s.c and intranasal PBS as control (herein referred as PBS/PBS-24h); (2) only vaccinated with BCG s.c. (BCG/PBS-24h), (3) only with an intranasal boost of Nano-FP1 (PBS/Nano-FP1-24h), and (4) animals received BCG s.c. and twelve weeks later one intranasal dose of Nano-FP1 (BCG/Nano-FP1-24h).

**Bacteria**
The H37Rv strain of *M. tuberculosis* was grown in Middlebrook 7H9 liquid medium (BD Biosciences, San Diego, CA) for 7–10 days and then sub-cultured in Proskauer Beck (PB) medium supplemented with 0.05% Tween 80 and 2% glycerol, until the mid-log phase. Bacterial stocks were aliquoted and stored at −80°C. Bacterial frozen stocks were used to infect mice via aerosol route, using a Glas-Col inhalation exposure system. Bacterial clumps were disrupted by forcing them through a 26G needle before diluting the bacterial suspension in water (Aqua B. Braun) to a concentration of $2 \times 10^6$ CFUs/ml to deliver 100 CFUs into the lungs.

**Infection and Sample Collection**
Mice were challenged via the aerosol route with the H37Rv strain at different time points (2–3, 7, and 11 weeks) following the last boost of the intranasal nanovaccines. Sample collection was conducted both pre- and post-challenge for each experimental group. Mice from the “pre-challenge” group were euthanized with CO₂ and lung parenchyma, bronchoalveolar lavage (BAL) and spleen were collected for analysis. The remaining animals (“post-challenge” group) were sacrificed four weeks after infection on each of the corresponding time points for organ CFU count. Lung parenchyma and spleen were collected from these mice for immunological assays.
Sample Processing
BAL was collected by irrigating lungs via trachea with a syringe containing 1 ml of cold PBS. Lungs and spleen were aseptically removed after BAL lavage and were homogenized and processed for immunological assays. Prior to homogenization, lungs were incubated in digestion medium DMEM (Dulbecco’s Modified Eagle Medium, High glucose NEAA, no glutamine, Gibco) supplemented with collagenase 0.15 mg/ml (Sigma Aldrich) at 37°C for 30 min. Spleens and collagenase-incubated lungs were homogenized and filtered through a 40 µm nylon mesh cell strainer (BD Biosciences, San Diego, CA) to obtain a homogenous cell suspension. BAL, lung and spleen cells were treated with red blood cell (RBC) lysing buffer (0.87% of NH₄Cl solution and 5% of PBS in water) for 5 min, and washed twice with DMEM supplemented with 10% of heat-inactivated fetal bovine serum. Leukocyte fraction was isolated by density gradient centrifugation on an 80%/40% Percoll (GE Healthcare, Sigma Aldrich) gradient. In mice sacrificed post-challenge, the left lung and half spleen were reserved for organ CFU count.

Bacterial Counts
The number of viable bacteria in lung and spleen from infected mice was determined by plating serial dilutions of the organ (left lung or half spleen) homogenates onto Middlebrook 7H11 agar (Difco Laboratories) supplemented with 10% OADC (Difco Laboratories). Colonies were counted after 3 weeks of incubation at 37°C with 5% CO₂ atmosphere.

Antibodies and Surface Staining
For analysis of general immune populations and lymphocyte composition in parenchyma lung and BAL, cell pools from 8 to 12 mice per group were used for the 2-week analysis and four mice per group for the 7, 12, and 14 weeks analysis.
Cells were incubated for 30 min with antibodies at 4°C, washed with FACs buffer (PBS with 3% FBS and 0.1% of 10 mM sodium azide) and kept at 4°C until flow cytometry analysis. List of antibodies used and references can be found in Table S1.

In the analysis of general immune populations, we identified CD4 T lymphocytes (CD45+ CD3+ CD4+ cells), CD8 T lymphocytes (CD45+ CD3+ CD8+ cells), B lymphocytes (CD45+ CD23- CD19+ cells), neutrophils (CD45+ Ly6G+ CD11b+), inflammatory monocytes (CD45+ Ly6G+ MHCII− CD64+ CD11b+ Ly6C+), resident monocytes (CD45+ Ly6G− MHCII− CD64+ CD11b+ CD11c+), NK cells (CD45+ Ly6G− MHCII− CD64− CD11b+), alveolar macrophages (CD45+ Ly6G-CD64+ Siglec-F+), exudate macrophages (CD45+ Ly6G−CD64+ Siglec-F− Ly6C+), interstitial macrophages (CD45+ Ly6G−CD64+ Siglec-F− Ly6C−), CD11b+ dendritic cells (CD45+ Ly6G−CD64− CD24+ MHCII+ CD11b+), CD11b−CD103+ dendritic cells (CD45+ Ly6G−CD64− CD24− MHCII+ CD11b− CD103+) and eosinophils (CD45+ Ly6G−CD64− CD24+ MHCII− CD11b+)) in lung, following cytometry gating strategy described in (27) and depicted in (Supplementary Figure S1).

For lymphocyte composition analysis, we identified central memory cells (CD45+ CD3+ CD4+CD8+ CD44+ CD62LHigh CD127+), effector memory cells (CD45+ CD3+ CD4+CD8+ CD62Llow CD127+), effector cells (CD45+ CD3+ CD4+CD8+ CD62Llow CD127−) and resident memory cells (CD45+ CD3+ [CD4+ CD44+ CD62Llow CD69+] or [CD8+ CD44+ CD62Llow CD69+ CD103+] following cytometry gating strategy depicted in (Supplementary Figure S1).

**Intracellular Cytokine Staining**

Cell pools from 8–12 mice per group were used for the 2 weeks analysis and three to four mice per group for the 7, 12, and 14 weeks analysis. Before intracellular cytokine staining, single cell suspensions (obtained from lung or BAL) from immunized animals (1 × 10⁶ cells) were stimulated for 5 h as follows: BCG group with Ag85 (5 µg/ml); BCG/Nano-FP1 group with Ag85 (5 µg/ml) and FP1 (5 µg/ml); BCG/Nano-FP2 group with Ag85 (5 µg/ml) and FP2 (5 µg/ml). 90 min after stimulation, 10 ng/µl of Brefeldin A (Sigma Aldrich) was added to the cells, and incubated for 3 h at 37°C to avoid cytokine release into the culture media. Cells were stained for 30 min at 4°C with antibodies directed to surface antigens in FACs buffer. Cells were then fixed and permeabilized with FACs buffer with 0.05% Saponin (Sigma Aldrich). Intracellular cytokine staining was performed staining the cells with the intracellular antibodies for 30 min at 4°C. After that, cells were washed with FACs buffer and kept at 4°C until flow cytometry analysis, following cytometry gating strategy depicted in (Supplementary Figure S1). List of antibodies used and references can be found in Supplementary Table S1.

**Flow Cytometry and Data Analysis**

Samples were run on an LSRII flow cytometer (BD Bioscience), and data were analyzed using Flowlogic (version 7.1, FlowLogic; UK) software. Graphpad Prism version 6.00 for Windows (GraphPad Software; CA, USA) was used for statistical analysis and graph representation.

**RNA Sequencing**

RNA from BAL cells and immune lung infiltrate was extracted using RNAeasy Plus Micro kit (Qiagen) according to the manufacturer’s recommendations. For early response experiments, RNA was extracted from the post-caval lung lobes using the RNAeasy Plus Mini kit (Qiagen) according to the manufacturer’s recommendations. RNA quality was assessed based on RIN value using Agilent 2100 Bioanalyzer and the Agilent RNA 600 Nano Kit (Agilent Technologies). Three samples of pooled RNA were analyzed per condition, selecting those with higher RIN value and RNA concentration. In the case of mice sacrificed at 11 and 14 weeks, two BAL samples were analyzed due to low RNA amount.

RNA sequencing was performed on an Ion Proton sequencer (Ion Torrent, Thermo Fisher Scientific; CA, USA) at the Genomic Service at the Centro de Apoyo Científico-Tecnológico à Investigación of University of Vigo (CACTI). Poly(A)-mRNA fraction was enriched using the Dynabeads® mRNA DIRECT™ Micro Kit (Thermo Fisher Scientific). Enriched mRNA was processed with the Ion Total RNA-Seq Kit v2 (Life technologies-Thermo Fisher Scientific). cDNA libraries with a percentage of DNA in 50 to 160 bp less than 50% passed the quality control and were then used for template preparation. Enriched templates were loaded in an Ion PI Hi-Q Chef Kit P1 chip and used for RNA-sequencing. Ion Proton Torrent Suite Software 5.4.0 filtered polyclonal reads (Ion Sphere Particles with >1 unique library template population), adapter dimers (reads where no or only a very short sequencing insert is present) and low quality reads (reads with unrecognizable key signal, low signal quality, and reads trimmed to < 25 bp). Usable raw data were recorded on FastQ files.

**RNA-seq Data Processing**

FastQ files resulting from RNA-sequencing were processed using the computational resources of the Galician Supercomputational Centre (CESGA). FastQ files were analyzed using FastQC software to confirm they had an average per base Phred quality score 20 to 30. Index was generated using Rsem software (version 1.2.31) utilizing reference genome of Mus musculus Ensembl Version GRCm38 and gene transfer format (.gtf) annotation from Ensembl version GRCm38.90. Alignment and count quantification were performed using STAR (version 2.5) and Rsem (version 1.2.31) software respectively.

**Differential Gene Expression Analysis**

Differential gene expression between groups was assessed using DESeq2 R package (version 1.20.0). Study groups were compared to each other and the differential expression between groups was evaluated based on the adjusted p-value and the absolute log2 fold change. Benjamini Hochberg correction was used to obtain adjusted p-values. Genes with adjusted p-value < 0.05 and absolute log2 fold change ≥ 0.6 were considered significant in terms of differential expression.
Pathway Enrichment Analysis
Pathway enrichment analysis of significantly differentially expressed genes was performed using ReactomePA R package (version 1.26.0) (28). Pathways and biological processes with p value <0.05 were considered significantly enriched. Representation of enrichment analysis in clusters was performed using clusterProfiler R package (version 3.10.1) (29).

Quantitative Real-Time PCR Analysis
RNA-seq results were validated by quantitative real-time PCR (RT-qPCR). Individual mice RNA were reverse transcribed to cDNA using SuperScript II Reverse Transcriptase (Invitrogen). cDNA and primers were mixed with PowerUp SYBR Green MadeMix (Applied Biosystems) and analyzed in a 7900HT Fast Real-Time PCR system (Applied Biosystems). A list of primers is described in Supplementary Table S5. Four independent biological replicates and technical triplicates of BCG/Nano-FP1 and BCG/Nano-FP2 groups were used for BAL analysis. Two to four independent biological replicates and technical triplicates of Naive, BCG, BCG/Nano-FP1, and BCG/Nano-FP2 groups were used for lung parenchyma analysis. The β-actin gene was used as internal control. Relative expression levels were calculated using the comparative method 2−ΔΔCt. Log2 ratios of fold change were calculated and compared in both RNA-Seq and RT-qPCR platforms.

RESULTS
Memory After Vaccination With Bacille Calmette–Guérin/Nano-FP1: The Protective Effect After Boosting Decreases With Time
It was reported that a regimen of BCG vaccination followed by mucosal boosting with a novel nanovaccine Nano-FP1 provided enhanced protection against Mtb challenge compared to BCG alone (26). However, the Mtb challenge in these experiments was always scheduled 3 weeks after the second nanovaccine boost. Therefore, in this work we investigated the duration of protection provided by the Nano-FP1 nanovaccine. To do this, mice were vaccinated with BCG for 12 weeks at which point they received two i.n. boosts with the nanovaccine Nano-FP1 two weeks apart (Figure 1A). The non-protective Nano-FP2 (R. Reljic unpublished) was used as control. To determine the duration of protection conferred by the prime-boost regimen mice were challenged with Mtb through the aerosol route 2, 7, and 11 weeks after a second boost.

Our data confirmed that the combination of BCG priming followed by boosting with Nano-FP1 was more effective than only BCG in reducing the CFUs in lungs in mice infected 2 weeks after the second boost. On the other hand, BCG/Nano-FP2 did not improve upon the protection conferred by BCG alone. Nonetheless, the protection effect induced by the BCG/Nano-FP1 vaccine was lost after 7 and 11 weeks post vaccination (Figure 1B) indicating that protection conferred by this regimen is rapidly lost. To determine if memory could be recovered at long term, we administered an additional intranasal boost at 11 weeks with Nano-FP1 or Nano-FP2 vaccines. Although a reduction in the lung CFUs was observed in the BCG/Nano-FP1 group (0.39 log CFUs reduction on average in BCG/Nano-FP1 group vs BCG), it was not as strong as the protection achieved at 2 weeks (average 0.7 log CFUs reduction among BCG/Nano-FP1 and BCG alone at 2 weeks) (p value < 0.05) (Figure 1B).

CFUs analysis in spleen revealed that at 2 weeks no significant differences were found among groups receiving BCG/Nano-FP1 or BCG alone (Figure 1C). Strikingly, at 7 and 11 weeks the Nano-FP1 boost even hampered the observed BCG-systemic protection, increasing significantly the bacterial burden in spleen.

Our results pointed that two intranasal boosts with Nano-FP1 in animals previously BCG vaccinated conferred enhanced lung protection to the Mtb infection at short-term compared to BCG alone. However, this protection was lost after 7 weeks and thereafter. Re-exposure by an extra vaccine boost reduced the CFUs, but to a lesser extent than expected after recalling immunological memory.

Protection Induced by Bacille Calmette–Guérin/Nano-FP1 Associates With an Increase in CD4 T Cells and Interstitial Macrophages
With the aim to correlate the protection levels observed at the various time points with the immune signature, we used flow cytometry to define the immunophenotypic profile including T cell phenotype and cytokine production (Figure 2A).

First, we identified total lung CD4+, CD8+ and B lymphocytes, neutrophils, inflammatory and resident monocytes, NK cells, alveolar, interstitial and exudate macrophages, conventional dendritic and CD11b- CD103+ dendritic cells and eosinophils. From all the cell subsets analyzed, we only found statistically significant changes in the increased number of CD4+ T cells and interstitial macrophages in the BCG/Nano-FP1 group 2 weeks after the 2nd nanovaccine boost (Figure 2B). We also detected a tendency of a lower percentage of neutrophils at this time, although these differences were not statistically significant.

We wanted to find out how these populations behave at long term in the lung, and found two features. First, the higher proportion of CD4+ T cells observed at 2 weeks in the BCG/ Nano-FP1 group was partially lost at 7 weeks and completely gone at 11 weeks (Figure 2C). Secondly, at 11 weeks the percentage of neutrophils in the BCG/Nano-FP1 group increased abruptly (Figure 2D).

No significant differences in cell subsets were observed in lungs between the Naive and BCG groups at the time-points studied (Supplementary Figure S2).

Bacille Calmette–Guérin/Nano-FP1 Induces an Increase in Resident Memory CD4 T Cells
Next, we focused on changes in the lymphocytic T cell subpopulations, analyzing the phenotype of T cell subtypes in lungs. These included the central memory, effector memory, effector and resident memory (RM) cells in both CD4+ and CD8+ subsets.
A higher proportion of activated lymphocytes (CD4+ CD44+) in lungs of BCG/Nano-FP1 immunized mice at 2 weeks (Figure 3A) was observed, with an increasing significant proportion of CD4+ RM lymphocytes, when compared to the other groups (Figure 3B). This predominant CD4+ CD44+ feature was partially lost at 7 and 11 weeks, which also correlates with the lower level of protection against the Mtb infection at these time points. In contrast, after the administration of the 3rd boost, CD4+ RM cells reached similar levels to those showed at short-term. BCG/Nano-FP2 also seemed to increase the proportion of activated CD4+CD44+ and CD4+ RM cells, although not reaching statistical significance.

Besides, both nanovaccines augmented the proportion of activated CD8+ CD44+ and CD8+ RM at short-term in a similar fashion (Figures 3C, D). Unlike CD4+ behavior, at 14 weeks we found a smaller proportion of CD8+ both activated and RM cells compared to 2 weeks. Moreover, no significant differences were observed between Naive and BCG mice at the time-points studied between different groups (data not shown). The immunophenotypic analyses showed that vaccination with BCG/Nano-FP1 induced significant changes in lung lymphocyte population at short-term, more pronounced than BCG/Nano-FP2, which were lost from 7 weeks and later on. We observed changes in both CD4+ activated lymphocytes and CD4+ RM cells. Also, administration of an extra boost of the nanovaccine recovered those lung cell populations in a similar manner.

**Bacille Calmette–Guérin/Nano-FP1 Induces Specific Profiles of Mono and Polyfunctional CD4 T Cells**

In order to assess the profile of cytokines induced by the BCG/Nano-FP1 vaccine compared to the other vaccination regimes, lung and spleen cells were checked for specific activation following in vitro re-stimulation for 5 h with Mtb antigens. We studied the production of IFNγ, TNFα, IL-2, and IL-17 by intracellular staining in activated CD45+ CD3+ CD4+/CD8+ CD44+ cells.

The number of CD4 cells producing one or combinations of cytokines was higher in the BCG/Nano-FP1 group at 2 weeks, but decreased at 7 weeks and even more at 11 weeks. However, the 3rd boost increased again at 14 weeks the percentage of cells producing either one or more cytokines, resembling the initial 2 weeks levels (Figure 4A). Examining in detail the polyfunctional signature in mouse lungs at 2 weeks after receiving the Nano-FP1 vaccine, we found an increment of CD4+ T cells producing either IFNγ, TNFα, or IL-17, or combinations of IFNγ+ TNFα+ and IFNγ+ TNFα+ IL-2+ (Figure 4B), compared to the other groups.

At 14 weeks, after the extra boost, a similar profile to the 2-week signature was observed, with even higher percentages of TNFα+ and IFNγ+ TNFα+ producing cells (Figure 4C). Thus, the 2-week effect on secreting cytokines induced by BCG/Nano-FP1 can be rescued by an additional intranasal boost.

Regarding CD8+ T cells cytokine profile, we found that both nanovaccines Nano-FP1 and Nano-FP2 increased the percentage of cells producing IFNγ alone or in combination with TNFα in a similar manner (Supplementary Figure S3).

No significant differences were observed in lungs between Naive and BCG groups of mice at the studied time-points. Similarly, no significant differences were found between lung and bronchoalveolar cells, or splenocytes from the different groups (data not shown).

The outstanding CD4+ cytokine response following Nano-FP1 boosting at 2 and again at 14 weeks points toward a classical memory boosting effect that nonetheless does not enhance TB protection at long term.

**Early Lung Transcriptome Alterations Arise in Response to Nano-FP1**

It is accepted that one of the most important factors in vaccination strategies is the election of effective adjuvant and delivery systems. To understand the possible causes of the short duration of protective and immunological memory induced by the BCG/Nano-FP1 vaccine, we first studied the ability of the nano-PolyIC system to create, in a very early phase, a lung environment able to support subsequent protective immune responses.

We analyzed mice lung transcriptome by RNA-sequencing just 24 h after the boost. Rapid and substantial transcriptional changes were observed after one single dose of Nano-FP1 intranasal administration. Differential gene expression analysis of each group versus control revealed a total of 55, 162 and 717 Differentially Expressed (DE) genes in BCG-24h, PBS/Nano-FP1-24h, and BCG/Nano-FP1-24h boosted groups, respectively (Figure 5A). This immediate effect points toward the mobilization of innate immune responses promoted by the vaccine delivery system. Remarkably, the considerably higher number of DE genes in BCG/Nano-FP1-24h mice reflects the importance of BCG priming in the outcome.

Analysis of enrichment pathways of up and downregulated DE genes, reflected how both BCG primed and non-primed Nano-FP1 shared some features, as upregulation of chemokine and Interferon signaling pathways (Figure 5B, Supplementary Table S2). Nonetheless, BCG/Nano-FP1-24h involved some unique pathways, related to antigen presentation, immunological interaction and synapses or triggering of complement, among others.

In summary, the analysis of changes induced by the BCG/Nano-FP1 vaccine at this early time point regarding various innate system related parameters, suggest a robust and powerful adjuvant effect.

**Bacille Calmette–Guérin/Nano-FP1 Induces Pronounced Changes in the Transcriptomic Profiles of Both Bronchoalveolar Lavage and Lung Shortly After Boosting**

Our following steps comprised the RNA-Sequencing analysis of Naive, BCG, BCG/Nano-FP1 and BCG/Nano-FP2 vaccination groups at short and long-term (2, 11, and 14 weeks). The aim was to reveal possible unique transcriptional changes correlated with the enhanced TB protection conferred by BCG/Nano-FP1 at 2 weeks and its subsequent disappearance. We analyzed independently bronchoalveolar lavage (BAL) cellular fraction and lung parenchyma to uncover potential specific mechanisms occurring in different lung compartments.

Differential gene expression analysis comparing BCG, BCG/Nano-FP1 or BCG/Nano-FP2 groups versus control group...
FIGURE 3 | Analysis of CD4 and CD8 T cell subtypes in lung. Groups of mice were vaccinated as described in Figure 1. Cells were analyzed by flow cytometry at 2, 7 and 11 weeks after the 2nd nanovaccine boost and at 14 weeks, 3 weeks after a third intranasal nanovaccine boost. (A, C) Data represent percentages of activated (CD44+) CD4 or CD8 T cells referred to the total of CD4+ or CD8+ T cells, respectively. (B, D) Graphs represent mean percentages (%) of T cell subtypes referred to the total of activated CD4+ or CD8+ T cells respectively ± standard error mean (SEM). Kruskal-Wallis test and Dunn’s multiple comparisons test were used for statistical analysis. *p < 0.05. *1: BCG/Nano-FP1% of resident memory CD4 T cells is significantly higher than those in Naive and BCG groups at 2 weeks. *2 and 3: BCG/Nano-FP1% of resident memory CD4 T cells are significantly higher than that those in BCG group at 7 and 14 weeks. *4, 5, 6 and 7: BCG/Nano-FP1 and BCG/Nano-FP2% of resident memory CD8 T cells are significantly higher than those in BCG group at 7 and 14 weeks.
(Naïve), showed that at 2 weeks BCG/Nano-FP1 prompted major changes in the transcriptome, with 2,543 and 1,974 DE genes in BAL and lung, respectively (Figure 6A, Supplementary Figures S4A, B).

At 11 weeks, we found a different scenario. The number of DE genes in BCG/Nano-FP1 was markedly reduced to 623 and 616 genes in BAL and the lungs, respectively. After the 3rd boosting (14 weeks), the number of DE genes in BCG/Nano-FP1 rose again, reaching 929 genes in BAL and 2161 DE genes in the lungs (Figures 6A, B). Moreover, we observed that this group conserved part of its DE genes at these time-points (Supplementary Figures S4C, D). The transcriptomic analysis comparing samples at 2 and 14 weeks shows that both shared the highest number of DE genes, with a total of 771 in BAL and 744 in the lungs (Supplementary Figures S4C, D).

Conversely, BCG/Nano-FP2 group displayed similar ciphers of DE genes at 2, 11, and 14 weeks, while BCG group showed the lowest number of DE genes compared to Naïve in all studied time-points in both BAL and lungs (Supplementary Figures S4A, B).

**Biological Pathways Induced by Nano-FP1 Differ Over Time**

We performed an enrichment pathway analysis to compare the biological context induced by BCG/Nano-FP1 vaccination, analyzing the up and downregulated DE genes at different time points, revealing some compelling details.

In BAL, several immune-related routes were upregulated in all, at 2, 11, and 14 weeks, such as: Immuno-regulatory interactions between a lymphoid and a non-lymphoid cell, immunological synapse, co-stimulation by CD28 family, PD-1 signaling, ER-Phagosome pathway, TCR, and chemokine signaling (Figure 6C).

Some pathways upregulated exclusively at 2 weeks were IFNγ signaling, Integrin cell surface interactions, extracellular matrix organization, RIPK1-mediated regulated necrosis, phagocytosis (Role of phospholipids and Fc gamma receptor dependent phagocytosis), or MHC-II antigen presentation.

Downregulated DE genes routes were mostly related with cell cycle and cell metabolism in the three clusters. Other pathways shared exclusively among 2 and 14 weeks involved Cytokine,
Interleukin, B cell receptor (BCR), DAP12 and NF-κB signaling, and the Complement cascade.

In the case of lung parenchyma, part of the upregulated genes coincided with enriched pathways previously shared by 2 or 14 weeks in BAL, as co-stimulation by CD28, TCR signaling, immunological synapse, or PD-1 signaling (Figure 6D).

Other routes matched with those pathways occurring exclusively in BAL at 2 weeks, for example MHC-II antigen presentation or role of phospholipids in phagocytosis. Moreover, new unique pathways were found induced by the BCG/Nano-FP1 vaccine at 2 weeks in the lung, as Reactive oxygen species (ROS) and Reactive nitrogen species (RNS) production in phagocytes, Scavenger receptors, endosomal TLR, signaling through P2Y receptors, Sphingolipid metabolism or regulation of Insulin-like Growth Factor. Compared to BAL, a smaller fraction of pathways was shared among 2 and 14 weeks, including Cholesterol biosynthesis, Cytokine and Interleukin signaling, ER-Phagosome pathway, Antigen presentation or Metabolism of carbohydrates.

Distinct biological mechanism related with DE genes were found in the lung compartments of BAL and parenchyma. Although most immune-related routes were found at the three time points studied, samples from animals obtained at 2 weeks after immunization or just after the third boost (at 14 weeks), displayed a more resembling profile in BAL than in lung parenchyma.

**Bacille Calmette–Guerin/Nano-FP1 Shows a Unique List of Differentially Expressed Genes at 2 Weeks**

The large number of DE genes obtained in the BCG/Nano-FP1 group hindered a more detailed analysis of single genes involved in the Nano-FP1 boosting protective effect at short-term. Our
next approach involved the filtering of the genes differentially expressed in BCG/Nano-FP1 at 2 weeks to obtain a reduced list of possible candidate biomarkers of Mtb enhanced protection.

BCG/Nano-FP1 group was pairwise compared by differential expression analysis to the other vaccination groups (Naive, BCG and BCG/Nano-FP2 for every time-point (2, 11, or 14 weeks). Then, three characteristic lists of genes of BCG/Nano-FP1 for 2, 11, and 14 weeks were obtained by the intersection of the differentially expressed (DE) genes set in mentioned pairwise comparison, i.e. genes differentiating BCG/Nano-FP1 from every other group. From the new sets of genes in each time point, we selected the relative complement of BCG/Nano-FP1 at 2 weeks’ genes. Thus, we obtained a list of candidate genes (22 in BAL and 29 in lung) (Figure 7, Table 1) that were exclusively DE in
the BCG/Nano-FP1 group at 2 weeks, at its highest point of Mtb protection. The filtering strategy scheme is described in Supplementary Figures S4E, F.

Most of the candidate genes were related to immune defence mechanisms. They include: upregulated T cell receptor (Trbv16, Trav13-2, Trav3-3) and genes coding for immunoglobulin chains (Ighv2-7, Ighv1-135, Ighv9-3, Ighv1-133, Ighv1-117, Ighg2c); cytokine-related genes (Ccl17 downregulated, Ccl8 upregulated); a couple of genes related to macrophages including upregulated Argpl2 and downregulated Mgl2; upregulated genes coding for Complement cascade (C1s1 and C3), upregulated H2-M2 as part of MHC class Ib, increased expression of Nitric oxide synthase Nos2 and Toll-like receptor Tlr12, genes of extracellular matrix related proteins, or downregulated cathepsin K gene (Ctsk). Three DE genes were shared in BAL and Lung, two of them upregulated: Htra1 (serine protease HTRA1) and T cell receptor alpha variable (13-2), and one downregulated, Cathepsin K.

**Validation of Differential Gene Expression by RT-qPCR**

To confirm the reliability of the gene expression results by RNA-Seq, we validated by RT-qPCR a total of 17 DE genes from the list of top-expressed candidate genes at 2 weeks: Nos2, H2-M2, Trbv16, Itgam, Cd38, Htra1, Ccl17, Gmpr, Mlph, F7, Bok, and Cspg4 in BAL and Cdo1, Ms4a7, Trbv16, Htra1, Car4, Cox6b2, and Ctsk in lung parenchyma samples. Due to low RNA amount, we analyzed BCG/Nano-FP1 vs BCG/Nano-FP2 groups in BAL. To increase robustness, we used biological replicates from independent mice, and we compared log2 fold changes obtained by both methods.

As it is shown in Table 2, we found similar expression levels in all comparisons, validating the results obtained by RNA-Seq for these genes.

**DISCUSSION**

Several novel TB vaccine candidates are currently in Phase II/III clinical trials (1) but despite major advances in TB research and vaccine development, BCG remains the only licensed TB vaccine to be used in humans. Development of new and more effective TB vaccines is a global priority. However, the lack of validated immune correlates of protection is a major hurdle in the development of novel vaccines.

Respiratory mucosal vaccination is proposed to be the most effective strategy, mimicking the natural route of Mtb infection in the lungs and thus inducing a better local immune response (16, 18, 30). Further, intranasal mucosal route has garnered attention due to its non-invasiveness and accessibility, allowing easy repeated vaccination if necessary (12–15, 17). It has also been observed in novel vaccination strategies that a better outcome could be achieved by the combination of systemic BCG-given immunity reinforced by mucosal boosting. Although BCG has moderate and heterogeneous efficacy on TB, it has a proven role in lowering infant mortality (31). Therefore, BCG vaccination is still a common practice in many countries which is advantageous as an effective priming for this type of vaccination strategy.

In the current study, we aimed to analyze the factors contributing to the duration of immunological memory after vaccination and also to make a correlation between immunological responses and protection. For this, we have used two candidate vaccines namely Nano-FP1 and Nano-FP2 together with BCG and extended the time of infection after vaccination from the short time (2 weeks) to 7 weeks and later. We consider of major importance when assessing novel vaccines, not only to determine the responsiveness of the immune system, but the durability of protection. We investigated the effect of these nanovaccines at different time-points and identified the protection-related immunological signature and genes mobilized in response to the vaccine.
Our results confirm previous data showing the efficacy of the BCG/Nano-FP1 vaccine in animals infected short time (2 weeks) after a second boost with the nanovaccine, by lowering the number of CFUs and triggering several changes in immune cell populations (26). However, both the protection and the phenotype profile were partially lost after 7 weeks and beyond. We found several changes in immune populations at 2 weeks after the 2nd Nano-FP1 boost, with an increased proportion of both CD4+ and CD8+ T cells, higher percentages of RM CD4+ and CD8+ T cells, and CD4+ cells synthesizing cytokines (IFNγ, TNFα, and/or IL-2), either monofunctionally or polyfunctionally. A partial modulation of the immune profile was also observed in mice receiving the

| TABLE 1 | List of candidate genes in bronchoalveolar lavage and lung cells, differentially expressed in the BCG/Nano-FP1 group at 2 weeks, compared to the other groups (naïve, BCG, BCG/Nano-FP2). |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Bronchoalveolar lavage** | **Gen symbol** | **Ensemble gene ID** | **Protein codifying** | **Log2 fold Change** |
| Nos2 | ENSMUSG000000020826 | Nitric oxide synthase, inducible | 3.72 |
| H2-M2 | ENSMUSG000000016283 | Histocompatibility 2, M region locus 2 | 3.68 |
| Trbv16 | ENSMUSG000000076473 | T cell receptor beta, variable 16 | 3.54 |
| Itgam | ENSMUSG000000030786 | Integrin alpha-M | 3.29 |
| Cd38 | ENSMUSG000000029084 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | 3.10 |
| Htra1 | ENSMUSG0000000068205 | Serine protease HTRA1 | 2.86 |
| Trav13-2 | ENSMUSG000000076846 | T cell receptor alpha variable 13-2 | 2.61 |
| Cnn3 | ENSMUSG000000053931 | Calponin-3 | 2.59 |
| Lgtf2r | ENSMUSG000000023830 | Cation-independent mannose-6-phosphate receptor | 2.46 |
| Procr | ENSMUSG000000027611 | Endothelial protein C receptor | 2.25 |
| Ctsk | ENSMUSG000000028111 | Cathepsin K | 1.38 |
| Ccl17 | ENSMUSG000000026303 | GMP reductase 1 | 1.43 |
| Mlph | ENSMUSG000000026303 | Melanophilin | 1.44 |
| Cspg4 | ENSMUSG00000032911 | Chondroitin sulfate proteoglycan 4 | 1.91 |

| Lung parenchyma | **Gen symbol** | **Ensemble gene ID** | **Protein codifying** | **Log2 fold Change** |
|----------------|----------------|------------------|------------------|------------------|
| Cdo1 | ENSMUSG000000030322 | Cysteine dioxygenase type 1 | 3.19 |
| Gpr162 | ENSMUSG000000038390 | Probable G-protein coupled receptor 162 | 3.03 |
| B4galnt4 | ENSMUSG000000055629 | N-acetyl-beta-glucosaminyl-glucoprotein 4-beta-N-acetylgalactosaminyltransferase 1 | 2.92 |
| Ms4a7 | ENSMUSG000000024672 | Membrane-spanning 4-domains, subfamily A, member 7 | 2.73 |
| Ccl8 | ENSMUSG000000026303 | C-C motif chemokine 9 | 2.41 |
| Ighg2b | ENSMUSG000000026303 | Immunoglobulin heavy constant gamma 2B | 2.37 |
| Lgals3bp | ENSMUSG00000033880 | Galectin-3-binding protein | 2.32 |
| Tmeff1 | ENSMUSG000000028347 | Tomoregulin-1 | 2.24 |
| Trav13-2 | ENSMUSG000000076846 | T cell receptor alpha variable 13-2 | 2.10 |
| Ighg2c | ENSMUSG000000026303 | Immunoglobulin heavy constant gamma 2C | 2.08 |
| Rgs16 | ENSMUSG000000026475 | Regulator of G-protein signaling 16 | 2.03 |
| Angptl2 | ENSMUSG00000004105 | Angiopoietin-related protein 2 | 2.01 |
| Trbv16 | ENSMUSG000000076473 | T cell receptor beta, variable 16 | 1.94 |
| Tlr12 | ENSMUSG000000062545 | Toll-like receptor 12 | 1.84 |
| Htra1 | ENSMUSG0000000068205 | Serine protease HTRA1 | 1.81 |
| Ighv1-133 | ENSMUSG000000094491 | Immunoglobulin kappa variable 1-133 | 1.58 |
| Trav3-3 | ENSMUSG000000094828 | T cell receptor alpha variable 3-3 | 1.52 |
| Ighv6-8 | ENSMUSG000000104452 | Immunoglobulin heavy variable 8-8 | 1.49 |
| Cpne2 | ENSMUSG000000034361 | Copine-2 | 1.48 |
| Lpcat2 | ENSMUSG000000033192 | Lyso phosphatidylcholine acyltransferase 2 | 1.38 |
| Ighv1-117 | ENSMUSG000000094335 | Immunoglobulin kappa variable 1-117 | 1.09 |
| Dusp4 | ENSMUSG000000031530 | Dual specificity protein phosphatase 4 | 0.90 |
| Ctsk | ENSMUSG000000028311 | Cysteine protease K | −0.76 |
| Dmd | ENSMUSG000000045103 | Dystrophin | −0.85 |
| Car4 | ENSMUSG000000008085 | Carbonic anhydrase 4 | −1.00 |
| Cox6b2 | ENSMUSG000000051811 | Cytochrome c oxidase subunit 6B2 | −1.06 |
| 6720489N17Rik | ENSMUSG000000072066 | KRAB domain-containing protein | −1.25 |
Nano-FP2, which could be explained as a boost of the BCG immunization, by the intranasal administration.

At short term after immunization, our results are in accordance with the central dogma of TB immunity, where CD4\(^+\) Th1 cells represent the major T cell subset that participates in the immune response to Mtb (4–6, 32, 33). Also, their secreted proinflammatory cytokines (IFN\(\gamma\), TNF\(\alpha\), and IL-2) are essential for control of bacterial growth in both animal models and humans, by the activation of macrophages (4–6, 32, 33). More recently IL-17+ (34) and polyfunctional CD4\(^+\) T cells, able to produce multiple cytokines, were also associated with protection (7–9, 35–37). Resident memory (RM) vaccine-induced T cells have been postulated as a new desired target due to their lung-homing capacity, with promising results (17, 25), including Hart et al. (26). Our work confirms previous results, with elevated percentages of CD4\(^+\) and CD8\(^+\) RM cells in BCG/Nano-FP1 group. However, this profile was lost at later time points.

Since the phenotypic profile observed at 2 weeks was lost from 7 weeks on, we wondered whether the administration of a third intranasal nanovaccine boost could recover the immune phenotype. In fact, most of the mobilized CD4 population observed at week 2, including total and RM CD4\(^+\) T cells, reached similar levels to short-term and a clear increase was observed in the number of total cytokine-secreting cells compared to the 2 weeks profile, especially in the number of TNF\(\alpha\)+ and IFN\(\gamma\)+ TNF\(\alpha\)+ producing CD4\(^+\) cells. On the contrary, the levels of total and RM CD8\(^+\) cells did not reach the same profile found at 2 weeks. One limitation of this study is the absence of intravascular staining to discriminate lung parenchyma immune cells from those from blood, a technique that has gained attention in the last decade (38–42). The analysis of the T cell homing markers indicates an important role of the tissue-resident cells in the response to the BCG/Nano-FP1 vaccine, although further studies could confirm the origin of those lymphocytes in lung parenchyma. Moreover, a fully understanding of the immune cell dynamics and migration might reveals new insights into the effects induced by the nanovaccine.

In summary, and opposed to the 2-week scenario, the recovery of the immunological profile, and even the cytokine polyfunctionality induced by the Nano-FP1 vaccine, was not enough to exert the expected increased protective effect against the Mtb, being even inferior to the levels reached at 2 weeks. These results suggest that Nano-FP1 repeated boosting set positive lung conditions at short term (2 weeks) that lowered bacterial load, but ultimately did not trigger an effective memory response at long term. Furthermore, our findings call for increased efforts when characterizing novel vaccines, by assessing both short and long-term outcomes.

In order to obtain more information, we were encouraged to analyze which genes were mobilized by BCG/Nano-FP1. We first investigated the type of response induced as soon as 24 h after the intranasal boost. We reasoned that analysis at this very short time would reveal the main innate effect of the vaccine and delivery system before the development of the adaptive immunity and in consequence, assess the capacity of the

### TABLE 2 | Comparison of the expression levels of 17 differentially expressed genes by RNA-Seq and RT-qPCR.

| Gen symbol | Lung parenchyma | Bronchoalveolar lavage |
|------------|-----------------|------------------------|
|            | BCG/Nano-FP1 vs Naive 2 weeks | BCG/Nano-FP1 vs BCG 2 weeks | BCG/Nano-FP1 vs BCG/Nano-FP2 2 weeks |
|            | RNA-Seq Log2 fold Change | RNA-Seq Log2 fold Change ± SEM | RNA-Seq Log2 fold Change | RNA-Seq Log2 fold Change ± SEM | RNA-Seq Log2 fold Change | RNA-Seq Log2 fold Change ± SEM |
| Nos2       | 3.96 ± 0.45      | 2.07 ± 0.30            | 0.95 ± 0.25 | 0.56 ± 0.25 | 1.12 ± 0.25 | 0.97 ± 0.25 |
| H2-M2      | 1.64 ± 0.30      | 1.24 ± 0.25            | 1.61 ± 0.36 | 2.06 ± 0.36 | 1.69 ± 0.36 | 1.89 ± 0.36 |
| Trbv16     | 1.97 ± 0.30      | 1.22 ± 0.25            | 1.69 ± 0.36 | 1.89 ± 0.36 | 1.95 ± 0.36 | 1.97 ± 0.36 |
| Itgam      | 0.96 ± 0.25      | 1.74 ± 0.33            | 1.09 ± 0.30 | 1.24 ± 0.30 | 1.14 ± 0.30 | 1.37 ± 0.30 |
| Ccl17      | 1.90 ± 0.30      | 1.17 ± 0.22            | 0.71 ± 0.16 | 0.95 ± 0.16 | 0.90 ± 0.16 | 1.04 ± 0.16 |
| Mip1       | 1.97 ± 0.25      | 1.22 ± 0.25            | 1.07 ± 0.25 | 1.24 ± 0.25 | 1.14 ± 0.25 | 1.37 ± 0.25 |
| F7         | 1.90 ± 0.25      | 1.17 ± 0.22            | 0.71 ± 0.16 | 0.95 ± 0.16 | 0.90 ± 0.16 | 1.04 ± 0.16 |
| Bok        | 1.90 ± 0.25      | 1.17 ± 0.22            | 0.71 ± 0.16 | 0.95 ± 0.16 | 0.90 ± 0.16 | 1.04 ± 0.16 |
| Cspg4      | 1.90 ± 0.25      | 1.17 ± 0.22            | 0.71 ± 0.16 | 0.95 ± 0.16 | 0.90 ± 0.16 | 1.04 ± 0.16 |
vaccine to create an appropriate environment in the lungs. This analysis asserted how one single Nano-FP1 boost prompted immediate and substantial transcriptomic changes. Nevertheless, comparative transcriptomic profiling among primed and non-primed Nano-FP1 provides compelling evidence of the relevance of BCG priming for the outcome. Furthermore, BCG/Nano-FP1 triggered mobilization of genes at 2 and 14 weeks in both BAL and lung parenchyma, but the response decreased at 11 weeks, suggesting its transient nature.

The main enriched pathways identified in the nanovaccine groups at 2 and 14 weeks in BAL were associated with many immune-related pathways such as cytokine signaling, TCR and BCR signaling or complement cascade. DAP12 signaling was also observed, involving DAP12-mediated activation signals in NK cells, granulocytes, monocytes/macrophages, and DCs (43, 44), although a published study associated activation of DAP12 to NK cells, granulocytes, monocytes/macrophages, and DCs (43, 44), although a published study associated activation of DAP12 in APCs with the delay in Th1 immunity in TB (45).

Moreover, we found pathways upregulated exclusively at 2 weeks, such as IFNγ signaling, cytokine known to be essential in TB defence (4–6) and antigen presentation by class II MHC, supporting a potentially significant role of CD4 T cells. Furthermore, Fc gamma receptor dependent phagocytosis pathway was upregulated, suggesting the contribution of that mechanism in elimination of invading pathogens mediated by immunoglobulins. Lastly, extracellular matrix organization and integrin interactions were also exclusively upregulated at 2 weeks. A role for the extracellular matrix has also been reported in regulating the host-pathogen interaction in TB (46).

In lung parenchyma, we found more differences among the transcriptome profiles in nanovaccine groups at 2 and 14 weeks. Around 1300 DE genes appeared unique to the BCG/Nano-FP1 group at 14 weeks, compared to the other time-points, which was ten times more than those DE genes found in BAL (Supplementary Figure S4). Regarding pathway enrichment analysis, we found that at 2 weeks, samples displayed a higher number of pathways with upregulated DE genes, most of them coinciding with immune-related pathways found in BAL. These intriguing differences among lung sections could reflect specific mechanisms involved in the enhancement (2 weeks) or not (14 weeks) in TB protection by BCG/Nano-FP1. Moreover, it should also be considered that the effect of a single (14 weeks) or double (2 weeks) boost with the nanovaccine could be the responsible for those differences, with a single dose triggering more easily changes in BAL than in the lung parenchyma. One of the most significant pathways shared among 2- and 14-week samples was surprisingly the cholesterol biosynthesis pathway. Although directly not immune-related, cholesterol has been reported as necessary for Mtb metabolism (47–49).

However, some new signatures, uniquely related to the 2 weeks post-immunization, were found in lung parenchyma, such as ROS and RNS production in phagocytes, Scavenger receptors, endosomal TLR, signaling through P2Y receptors, Sphingolipid metabolism or regulation of Insulin-like Growth Factor. ROS and RNS production have been well known as key macrophage bactericidal responses to Mtb, although the mycobacteria have developed sophisticated mechanisms to avoid them (50). Toll-like receptors play a key role in both innate immune responses and the initiation of adaptive immunity to Mtb, leading to phagocytic activation. TLRs including 2, 4, 9, and 8 are known to play critical roles in recognition of Mtb (51, 52). Regarding P2Y receptors, they activate intracellular signaling cascades to regulate a variety of cellular processes, including their use by macrophages to combat Mtb (53). Also, scavenger receptor pathways could participate in the Mtb infection outcome. Some scavenger receptors have been directly related to host and pathogenic cholesterol uptake, and to mycobacterial recognition by macrophages (54, 55).

No major changes in cell populations or transcriptome were found in the BCG-vaccinated groups, although its protective effect was evident. We cannot provide a better explanation than to propose different mechanisms of protection are involved and that the nanovaccine is promoting a pathway dependent of BCG, but BCG itself is inducing additional different pathways that are essential for protection.

As a large list of genes identified related with the transcriptional signature of nanovaccine-vaccinated mice, the refined analysis identified unique transcriptomic signature by BCG/Nano-FP1 at 2 weeks, obtaining a list of 22 genes in BAL and 29 in lung parenchyma (Table 1). Several T cell receptor (Trbvl6, Travl3-2, Trav3-3), immunoglobulin chains-coding genes (Ighg2b, Igkv1-135, Igkhv9-3, Igkv1-133, Igkv1-117, Igheg2c) and cytokine-related genes (Ccl17, Ccl8) were upregulated.

A couple of genes related to macrophages were identified, including the upregulated Angplt2, a secreted factor able to attract and activate macrophages, and Mgl2 Macrophage galactose N-acetyl-galactosamine-specific lectin 2, which was downregulated. Nos2 was also upregulated in BCG/Nano-FP1 group. Nos2 enzyme produces nitric oxide, which mediates bactericidal actions in macrophages, and has been described important in TB host defence. Among mechanism involved in triggering of the immune response, we found upregulated Cis1 and C3 coding for Complement proteins, and H2-M2 as part of MHC class Ib. Another key type of receptors that initiate immune responses to pathogens, TLRs, were represented with the augmented expression of Tlr12. Although little is known about this protein, recently a role of TLR12 was described in activating macrophages by Mtb antigens (56).

Lastly, we observed expression changes in some of the extracellular matrix related proteins, which may play an important role in extracellular matrix degradation in TB disease: serine protease HTRA1 (Htral) was upregulated, and cathepsin K gene (Ctsk) was downregulated in both BAL and lung. The collagenase has been reported previously to contribute to TB cavitation (57).

In keeping with previous observations, we believe this list of genes could be a valuable source of potential biomarkers correlated with protection, as they are driving local lung responses to Mtb infection.

Validation of RNA-Seq results was performed by quantitative RT-qPCR analysis of some of the top-fold change DE genes of BCG/Nano-FP1 group at 2 weeks. 17 genes were studied and both techniques showed similar gene expression levels (Table 2), supporting the reliability of our overall findings on the candidate
genes and biological pathways, that might play a role in TB protection.

Some of the validated genes are related to key defense pathways. Upregulated H2-M2 and Trbv16 genes might participate in increasing antigen presentation and recognition (as they codify for proteins of MHC-I and TCR, respectively), while overexpressed Cldn8 and Itgam might reflect changes in leucocyte populations, activation or migration (58, 59). As mentioned, upregulated Nos2 has long been known as a key element in ROS anti-mycobacterial response (60). Decreased expression of Ccl17 might favor the deviation of the immune population toward a Th1 response (61).

Our results also suggest the importance of other mechanisms in TB infection, for instance, upregulated membrane compound Ms4a7 was previously reported as altered in TB studies (62), being involved in signal cell transduction. The downregulated gene Bok is one of the less studied members of the BCL-2 family, and no critical function has been assigned yet, although they work as critical regulators of apoptosis (63). Our findings also indicate an important role for the extracellular matrix organization, a pathway upregulated in the enrichment analysis of BCG/Nano-FP1 BAL at 2 weeks, with three validated genes possibly participating in the process: Htral (64), Ctsk (57) and Gmp4 (65).

For other validated genes, although presenting major fold change differences, we could not provide feasible hypotheses for their potential role in TB protection or immune system functioning, as is the case of Cdo1 (Cysteine Dioxygenase Type 1, upregulated), F7 (Coagulation Factor VII, downregulated), Gmpr (Guanosine monophosphate reductase 1, downregulated) or Mlph (Melanophilin, downregulated). We encourage future studies to target the wide range of altered pathways and biologically appealing DE genes found in this work.

Results obtained from both phenotypic and gene expression analysis suggest that the protective state achieved at short term after the nanovaccine boosting might be a combination of both lymphocytic and innate immune fractions. However, the precise role in bacterial control of the different leukocyte populations is poorly understood. While the participation of T cells, especially tissue-resident T cells, is known to be essential in TB protection, several research lines have moved toward the study of the innate fraction, particularly in light of the critical importance of early bacterial control on the outcome of the infection (66–69). We detected changes on gene expression as soon as 24 h after the first nanovaccine boosting, pointing toward the action of innate immune cells. Whether these changes are due to long-term epigenetic reprogramming (“trained immunity”) or not, remains to be cleared. Further work involving depletion of specific immune populations and adoptive transfer experiments could help to establish the contribution of each population to the protective outcome. Analysis of the post-translational modifications driven by the nanovaccine on the innate cell population, will be considered in future investigations.

In summary, we show here that immune responses and long-term protection are not well correlated. Protection against Mtb infection promoted by the BCG/Nano-FP1 vaccine candidate and possibly other vaccines, is of short duration and may require a number of frequent boosts to keep the protective ability of the vaccine. A partial recovery of the immunological profile and protection could be improved, but the maintenance of this long-term protection requires further investigation. Several mechanisms have been identified that could explain the enhanced protection of the vaccine at 2 weeks after the intranasal boost. We provide a list of genes that are exclusively up or downregulated during the “protection window,” which could provide new information for TB vaccine design. Further, we consider that TB protection is established by a complex cooperation of several immune populations, including CD4+, CD8+ and innate cells, driving specific and a tight gene regulation. Thus, this study proposes a list of genes and distinct molecular pathways to be considered as important when directing future TB vaccine efforts and research.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The name of the repository and accession number can be found here: https://www.ebi.ac.uk/arrayexpress/, E-MTAB-9449.

ETHICS STATEMENT

The experimental animal procedures were approved by Vigo University Committee and authorized by the competent authority (Xunta de Galicia, Conselleria do Medio Rural, Pontevedra, Spain) and by Stockholm North Ethical Committee on animal experiments.

AUTHOR CONTRIBUTIONS

AM-P performed RNA purification, analyzed the experimental data, and wrote the paper with input from all other authors. AM-P, AI, OE, and CMF performed most animal procedures and sample processing. AC helped with the animal vaccinations. ET, AGC, and AI, OE, and CMF performed most animal procedures and sample processing. AG-F conceived the study, made the drafting and the article and approved the submitted version.

FUNDING

This work was supported by the projects EU Horizon2020: “Eliciting Mucosal Immunity in Tuberculosis” (EMI-TB) project (Grant Number 643558); Portugal National funds, through the Foundation for Science and Technology (FCT) -
project PTDC/SAU-INF/28463/2017, UIDB/50026/2020, and UIDP/50026/2020; NORTE-01-0145-FEDER-000013 and NORTE-01-0145-FEDER-000023, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). This work also received financial support from the Xunta de Galicia (Grupo de Referencia Competitiva [ED431C 2016/041]) and Centro singular de investigación de Galicia and the European Regional Development Fund (ERDF) [ED431G2019/06]. AP acknowledges a fellowship from Xunta de Galicia Programa de axudas á etapa predoutoral (Consellería de Cultura, Educación e Ordenación Universitaria) (ED481A-2018/230). ET was supported by the FCT investigator grant IF/01390/2014 and CMF through the FCT PhD fellowship PID/BD/137447/2018.

ACKNOWLEDGMENTS

The authors thank the specialized personnel of Genomics Facility, Centro de Apoyo Científico e Tecnológico á Investigación (CACTI) (University of Vigo, Vigo, Spain) for performing RNA-Sequencing, and Galician Supercomputational Centre (CESGA), whose services allowed the bioinformatics analysis.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.589863/full#supplementary-material

REFERENCES

1. Global Tuberculosis Report 2020. Geneva: World Health Organization. (2020). Licence: CC BY-NC-SA 3.0 IGO. Available at: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf.

2. Colditz GA, Brewer TF, Berkley JS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA (1994) 271(9):698–702. doi: 10.1001/jama.1994.0351030075038

3. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet (1995) 346(8986):1339–45. doi: 10.1016/S0140-6736(95)92238-9

4. Shimorata K, Kishimoto H, Takagi E, Tsunekawa H. Determination of the T-cell FineP for protection by BCG: implication for system immunization. J Immunol (1993) 151(1):518–25.

5. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol (2009) 27:393–422. doi: 10.1146/annurev.immunol.021808.132023

6. Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 T cells. J Immunol (2009) 182(12):8047–55. doi: 10.4049/jimmunol.0801592

7. Orme IM, Roberts AD, Gramm JP, Abrams JS. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J Immunol (1994) 151(1):518–25.

8. Cruz A, Torrado E, Carmona J, Fraga AG, Costa P, Rodrigues F, et al. BCG vaccine-induced long-lasting control of Mycobacterium tuberculosis correlates with the accumulation of a novel population of CD4+IL-17+TNF +IL-2+ T cells. Vaccine (2015) 33(1):85–91. doi: 10.1016/j.vaccine.2014.11.013

9. Smith SG, Zelmer A, Blitz R, Fletcher HA, Dockrell HM. Polymicrobial CD4 T-cells correlate with in vitro mycobacterial growth inhibition following Mycobacterium bovis BCG-vaccination of infants. Vaccine (2016) 34(44):5298–305. doi: 10.1016/j.vaccine.2016.09.002

10. Mendez-Samperio P. Role of interleukin-12 family cytokines in the cellular response to mycobacterial disease. Int J Infect Dis (2010) 14(5):e366–71. doi: 10.1016/j.ijid.2009.06.022

11. Ramirez-Alejo NS, Santos-Aruguelo L. Innate defects of the IL-12/IFN-γ axis in susceptibility to infections by mycobacteria and salmonella. J Interferon Cytokine Res (2014) 34(5):307–17. doi: 10.1089/jir.2013.0050

12. Falero-Diaz G, Challacombe S, Banerjee D, Douce G, Boyd A, Ivanyi J. Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine (2000) 18(28):3223–9. doi: 10.1016/S0264-410X(00)00134-1

13. Rodriguez A, Troye-Blomborg M, Lindroth K, Ivanyi J, Singh M, Fernandez C. B- and T-cell responses to the mycobacterium surface antigen PstS-I in the respiratory tract and adjacent tissues - Role of adjuvants and routes of immunization. Vaccine (2003) 21(5–6):458–67. doi: 10.1016/S0264-410X(02)00478-4

14. Chen L, Wang J, Zganiacza A, Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Society (2004) 72(1):238–46. doi: 10.1128/JID.21.238-246.2004

15. Wang J, Thorson L, Stokes RW, Santosuosso M, Hyugen K, Zganiacz A, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol (2004) 173(10):6537–65. doi: 10.4049/jimmunol.173.10.6537

16. Agullo N, Toledo AM, Lopez-Roman EM, Perez-Herran E, Gormley E, Rullas-Trincado J, et al. Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination. Clin Vaccine Immunol (2014) 21(4):594–7. doi: 10.1128/CVI.00700-13

17. Perdomo C, Zedler U, Kühll AA, Lozza L, Saikali P, Sander LE, et al. Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis. MBio (2016) 7(6):1–11. doi: 10.1128/mBio.01866-16

18. Verreck FAW, Tchilian EZ, Ververne RW, Sombrock CC, Kondova I, Eissen OA, et al. Variable BCG efficacy in rhesus populations: Pulmonary BCG provides protection where standard intra-dermal vaccination fails. Tuberculosis (2017) 104:46–57. doi: 10.1016/j.tube.2017.02.003

19. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AVS. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol (2003) 171(3):1602–9. doi: 10.4049/jimmunol.171.3.1602

20. Darrah PA, Bolton DL, Lackner AA, Kaushal D, Aye PP, Mehra S, et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of Rhesus macaques but fails to protect against high dose Mycobacterium tuberculosis challenge. J Immunol (2014) 193(4):779–811. doi: 10.4049/jimmunol.1400676

21. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guérin immunity. J Immunol (2006) 177(9):6353–60. doi: 10.4049/jimmunol.177.9.6353

22. Forbes EK, Sander C, Ronan EO, McShane H, Hill AVS, Beverley PCL, et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol (2008) 181(7):4955–64. doi: 10.4049/jimmunol.181.7.4955

23. Stylianou E, Diogo GR, Pepponi I, van Dolleweerd C, Arias MA, Locht C, et al. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. Eur J Immunol (2014) 44(2):440–9. doi: 10.1002/eji.201343887

24. Orr MT, Beece EA, Hudson TE, Argilla D, Huang PWD, Reese VA, et al. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the
28. Yu G, He QY. ReactomePA: An R/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst (2012) 16(2):477–9. doi: 10.1039/C5MB00663E

29. Yu G, Wang LG, Han Y, He QY. ClusterProfiler: An R package for comparing biological themes among gene clusters. Omics (2012) 16(5):284–7. doi: 10.1089/omi.2011.0118

30. Thomas ZRM, McShane H. Aerosol immunisation for TB: Matching route of vaccination to route of infection. Trans R Soc Trop Med Hyg (2015) 109(3):173–81. doi: 10.1093/trstmh/tru208

31. Higgins JPT, Soares-Weiser K, Lopez-Lopez JA, Kakourou A, Chaplin K, Christensen H, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: Systematic review. BMJ (2016) 355:i5170. doi: 10.1136/bmj.i5170

32. Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol (2012) 12(8):581–91. doi: 10.1038/nri3259

33. Urdahl KB. Understanding and overcoming the barriers to T cell-mediated immunity against tuberculosis. Semin Immunol (2014) 26(6):578–87. doi: 10.1016/j.smim.2014.10.003

34. Terrado E, Cooper AM. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev (2010) 21(6):455–62. doi: 10.1016/j.cgr.2010.10.004

35. Aagaard CS, Hoang TTKT, Vingsbo-Lundberg C, Dietrich J, Andersen P. Th1/Th17 cytokine profile of murine non-lymphoid tissues. PloS One (2013) 8(1):e51096. doi: 10.1371/journal.pone.0150606

36. Scriba TJ, Tameris MD, Mansoor N, Smit E, Van Der Merwe L, Isaacs F, et al. Differences in the pattern of murine dendritic cells and macrophages in response to Mycobacterium tuberculosis infection. PloS One (2016) 11(3):1. doi: 10.1371/journal.pone.0150606

37. Kubler A, Larsson C, Luna B, Andrade BB, Amaral EP, Urbanowski M, et al. The extracellular matrix regulates granuloma necrosis in tuberculosis. J Infect Dis (2015) 212(3):463–73. doi: 10.1093/infdis/jiv076

38. Jeyanathan M, McCormick S, Lai R, Afkhami S, Shaler CR, Horvath CN, et al. Pulmonary M. tuberculosis infection delays Th1 immunity via immunoadaptor DAP12-regulated IRAK-M and IL-10 expression in antigen-presenting cells. Mucosal Immunol (2014) 7(5):670–83. doi: 10.1038/mi.2013.86

39. Van Der Geize R, Yam K, Heusser T, Wilbrink MH, Hara H, Anderton MC, et al. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc Natl Acad Sci U S A (2007) 104(19):947–52. doi: 10.1073/pnas.0605728104

40. Pandey AK, Sassetti CM. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci U S A (2008) 105(11):4376–80. doi: 10.1073/pnas.0711591105

41. Anderson KG, Sung H, Lefrancois L, Deisinger A, Vezys V, et al. A thiolase of Mycobacterium tuberculosis is required for virulence and production of androstenedione and androstadienedione from cholesterol. Infect Immun (2010) 78(1):275–82. doi: 10.1128/IAI.00889-09

42. Vanossi MK, Bartek IL, Visconti K, Schoolnik GK. The response of Mycobacterium tuberculosis to reactive oxygen and nitrogen species. Front Microbiol (2011) 2(105):1–12. doi: 10.3389/fmicb.2011.00105

43. Kleinmijnenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R. Innate immune recognition of mycobacterium tuberculosis. Clin Dev Immunol (2011) 2011:405310. doi: 10.1155/2011/405310

44. Fardgohor M, Nikoueinejad H. New findings of Toll-like receptors involved in Mycobacterium tuberculosis infection. Pathog Global Health (2017) 111(5):256–64. doi: 10.1080/20477724.2017.1351080

45. Petit-Jentreau L, Tailleux L, Coombes JL. Purinergic signalling: A common path in the macrophage response against Mycobacterium tuberculosis and Toxoplasma gondii. Front Cell Infect Microbiol (2017) 7:1–7. doi: 10.3389/fcimb.2017.000347

46. Schäfer G, Guler R, Murray G, Brombacher F, Brown GD. The role of scavenger receptor class A-depleting mAb in the ovalbumin model. PloS One (2009) 4(12):1–13. doi: 10.1371/journal.pone.0008448

47. Sever-Chrona Z, Tvanineeram A, Hunter RL, Chronou ZC. Prolonged survival of scavenger receptor class A-deficient mice from pulmonary Mycobacterium tuberculosis infection. Tuberculosis (Edinb) (2011) 91 Suppl 1(Suppl 1):S69–74. doi: 10.1016/j.tube.2011.10.014

48. Su H, Zhu Z, Zhu L, Kong C, Huang Q, Zhang Z, et al. Mycobacterium tuberculosis latent antigen Rv2029c from the multistage DNA vaccine A39 drives TH1 responses via TLR-mediated macrophage activation. Front Microbiol (2017) 8:1–8. doi: 10.3389/fmicb.2017.02266

49. Kubler A, Larsson C, Luna B, Andrade BR, Amaral EP, Urbanowski M, et al. Cathepsin K contributes to cavitation and collagen turnover in pulmonary tuberculosis. J Infect Dis (2016) 213(4):618–27. doi: 10.1093/infdis/jiv438

50. Glaria E, Valledor AF. Roles of CD38 in the Immune Response to Infection. Cells (2020) 9(1):228. doi: 10.3390/cells9010228

51. Solovoj DA, Plukota E, Plow EF. Distinct roles for the α and β subunits in the functions of integrin αMβ2 J Biol Chem (2005) 280(2):1336–45. doi: 10.1074/jbc.M409689200

52. Macmicking JD, North RJ, Lacourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A (1997) 94(10):5243–8. doi: 10.1073/pnas.94.10.5243

53. Jang S, Uzelac A, Sálgame P. Distinct chemokine and cytokine gene expression pattern of murine dendritic cells and macrophages in response to Mycobacterium tuberculosis infection. J Leukoc Biol (2008) 84(5):1264–70. doi: 10.1189/jlb.03107742

54. Marquis JP, Kapoustina O, Langlais D, Ruddy R, Dufour CR, Kim BH, et al. Interferon regulatory factor 8 regulates pathways for Antigen presentation in
myeloid cells and during tuberculosis. PloS Genet (2011) 7(6):e1002097. doi: 10.1371/journal.pgen.1002097

63. Ke F, Voss A, Kerr JB, O’Reilly LA, Tai L, Echeverry N, et al. BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice. Cell Death Differ (2012) 19(6):915–25. doi: 10.1038/cdd.2011.210

64. Vierkotten S, Muether PS, Fauser S. Overexpression of HTRA1 leads to ultrastructural changes in the elastic layer of Bruch’s membrane via cleavage of extracellular matrix components. PloS One (2011) 6(8):e22959. doi: 10.1371/journal.pone.0022959

65. Tang F, Lord MS, Stallcup WB, Whitelock JM. Cell surface chondroitin sulphate proteoglycan 4 (CSPG4) binds to the basement membrane heparan sulphate proteoglycan, perlecan, and is involved in cell adhesion. J Biochem (2018) 163(5):399–412. doi: 10.1093/jb/mvy008

66. Winslow GM, Cooper A, Reiley W, Chatterjee M, Woodland DL. Early T-cell responses in tuberculosis immunity. Immunol Rev (2008) 225:284–99. doi: 10.1111/j.1600-065X.2008.00693.x

67. Petursdottir DH, Chuquimia OD, Freidl R, Fernández C. Macrophage control of phagocytosed mycobacteria is increased by factors secreted by alveolar epithelial cells through nitric oxide independent mechanisms. PloS One (2014) 9(8):2–11. doi: 10.1371/journal.pone.0103411

68. Adam L, López-González M, Björk A, Pálsson S, Pouc C, Wahren-Herlenius M, et al. Early resistance of non-virulent mycobacterial infection in C57BL/6 mice is associated with rapid up-regulation of antimicrobial cathelicidin Camp. Front Immunol (2018) 9(1939):1–13. doi: 10.3389/fimmu.2018.01939

69. D’Agostino MR, Lai R, Afkhami S, Khara A, Yao Y, Vaseghi-Shanjani M, et al. Airway Macrophages Mediate Mucosal Vaccine–Induced Trained In innate Immunity against Mycobacterium tuberculosis in Early Stages of Infection. J Immunol (2020) 205(10):2750–62. doi: 10.4049/jimmunol.2000532

Conflict of Interest: MS is the Founding Director of LIONEX Diagnostics & Therapeutics GmbH, based in Braunschweig. AG-F is a co-promoter of the spin-off company NanolImmunoTech, based in Vigo, Spain.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer NT declared a past co-authorship with several authors, A-LS and LA, to the handling editor.

Copyright © 2021 Martínez-Pérez, Igea, Estévez, Ferreira, Torrado, Castro, Fernández, Spetz, Adam, López González, Singh, Reljic and González-Fernández. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.